Alvotech (ALVO) and Advanz Pharma Holdco announced that the European Commission has approved Mynzepli as a biosimilar to Eylea or aflibercept, in a pre-filled syringe and vial. The centralized marketing authorization is valid in all European Economic Area countries.
Mynzepli is approved for all adult indications approved for the reference biologic, neovascular or wet age-related macular degeneration, or visual impairment due to macular oedema secondary to retinal vein occlusion, diabetic macular oedema or myopic choroidal neovascularization.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.